| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | President and CEO
1 company
Fred Aslan is Chief Executive Officer at ARTV. Fred Aslan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.1M at current prices.
Historically, Fred Aslan's trades have earned a below-average insider score of 40/100 across 5 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -48.7%.
The ARTV filings lean toward selling, a net 320,332 shares.
Fred Aslan has 16 Form 4 filings on record from July 2024 to November 2026, all as Chief Executive Officer at Artiva Biotherapeutics (ARTV), 2024–2026.
The 29 reported transactions were 10 open-market sales, 6 stock awards, 6 dispositions back to the company and 4 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 10 sales worth about $2.3M.
The largest open-market sale was 61,888 shares of ARTV at an average $11.16 on September 3, 2026, about $690K.
6 of the 10 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 4 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | ARTV Artiva Biotherapeutics, Inc. | Chief Executive Officer | Sell | 62,178 | $4.18 | $259,972.44 | -4.1% | - | - | |
| Oct 6, 2026 | ARTV Artiva Biotherapeutics, Inc. | Chief Executive Officer | Sell10b5-1 | 23,463 | $7.20 | $168,879.64 | -1.5% | - | - | |
| Oct 5, 2026 | ARTV Artiva Biotherapeutics, Inc. | Chief Executive Officer | Sell | 61,696 | $6.84 | $421,827.89 | -3.8% | - | - | |
| Sep 8, 2026 | ARTV Artiva Biotherapeutics, Inc. | Chief Executive Officer | Sell10b5-1 | 23,429 | $10.92 | $255,746.28 | -1.6% | - | - | |
| Sep 3, 2026 | ARTV Artiva Biotherapeutics, Inc. | Chief Executive Officer | Sell | 61,888 | $11.16 | $690,391.58 | -4.0% | - | - | |
| May 19, 2026 | ARTV Artiva Biotherapeutics, Inc. | Chief Executive Officer | Sell | 27,116 | $9.01 | $244,252.79 | -1.7% | +37.3% | - | |
| Dec 15, 2025 | ARTV Artiva Biotherapeutics, Inc. | President and CEO | Sell10b5-1 | 3,187 | $6.00 | $19,122.00 | -0.3% | -1.9% | - | |
| Nov 17, 2025 | ARTV Artiva Biotherapeutics, Inc. | President and CEO | Sell10b5-1 | 6,375 | $3.38 | $21,522.00 | -1.8% | +17.1% | - | |
| Oct 17, 2025 | ARTV Artiva Biotherapeutics, Inc. | President and CEO | Sell10b5-1 | 25,500 | $6.00 | $153,000.00 | -6.7% | -25.8% | -2.7% | |
| Aug 15, 2025 | ARTV Artiva Biotherapeutics, Inc. | President and CEO | Sell10b5-1 | 25,500 | $2.73 | $69,579.30 | -6.2% | +23.3% | +316.4% |